A comprehensive update to Dendritic Cell therapy for glioma: a systematic review and meta-analysis
- 8 March 2022
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 21 (4) , 1-19
Abstract
Gliomas are a major challenge of neuro-oncology due to high mortality and recurrence rates. Clinical applications of Dendritic Cells; as well-known immunotherapeutics has yielded promising results in the clinical trial pipelines over decades. In this systematic review, we critically discuss the current status, future perspective and challenges of dendritic cell therapy for gliomas in clinics and summarize the adjuvants and antigens used for dendritic cell therapy based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We used the Cochrane Collaboration’s tool to assess the bias risk in each trial. Furthermore, we summarize the study population and setting, study blinding, comparators, dosage, treatment regimens and durations, efficacy and safety issues of the clinical trials published on DC therapy for gliomas and also report the results of our meta-analysis on safety, and clinical/immunological efficacy of dendritic cell therapy for gliomas in the past decades. in the current review, 39 previous studies were considered eligible for meta-analysis, enrolling 1049 patients who received autologous dendritic cells and 558 as controls/historical controls. The results of our meta-analysis indicated that the most frequent grade I/II adverse event reported in phase I or phase I/II trials was fatigue (∼16% and 24%). Moreover, in phase II trials, fatigue and cytopenia were the most common adverse events (AEs) (∼9% and 14%). Meanwhile, Grade III/IV AEs were rare comprising peritumoral edema and neurotoxicity; seizures and hematotoxicity. Moreover, our meta-analysis yielded promising results for infiltration of CD8+T cells into tumor site ∼64% after DC therapy and IFNγ increase in ∼45% of the patients as an immunological response suggesting promising immunological efficacy for DC therapy for glioma. DC therapy could serve as a safe and potent immunotherapy strategy for gliomas however, still limitations exist to draw certain conclusions on the potential efficacy due to the diversity of the criteria applied to assess the clinical response (e.g., RANO, RECIST, Macdonald criteria, and iRANO) and limited data on patients’ survival.Keywords
This publication has 95 references indexed in Scilit:
- Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastomaCancer Immunology, Immunotherapy, 2013
- Comparison of Glioma-associated Antigen Peptide-loaded Versus Autologous Tumor Lysate-loaded Dendritic Cell Vaccination in Malignant Glioma PatientsJournal of Immunotherapy, 2013
- Mechanisms of Glioma-Associated NeovascularizationThe American Journal of Pathology, 2012
- Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastomaCancer Immunology, Immunotherapy, 2012
- A phase I/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant gliomaJournal of Clinical Neuroscience, 2011
- Immune Response in Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Intranodal Autologous Tumor Lysate-dendritic Cell Vaccination After Radiation ChemotherapyJournal of Immunotherapy, 2011
- RECIST revised: implications for the radiologist. A review article on the modified RECIST guidelineEuropean Radiology, 2009
- CNS immune privilege: hiding in plain sightImmunological Reviews, 2006
- Comparison of Two Methods to Detect Publication Bias in Meta-analysisJAMA, 2006
- Measuring inconsistency in meta-analysesBMJ, 2003